America Great Health reports interim data from ion-modified peptide adjunctive therapy observational study in solid tumors
AAGH•Interim observational study data
America Great Health released an interim summary from a December 2024–May 2026 observational study of ion-modified peptide adjunctive therapy.
Results have already been presented in the Form 8-K report, not deferred to a future presentation.
Reported outcomes were described as acceptable across most participants receiving standard cancer care alongside the peptides, with responses characterized as marked in selected cases.
Safety findings and participant withdrawals
Two advanced solid-tumor participants withdrew and later died from disease-related multi-organ failure, prompting tighter future eligibility criteria.
Safety was described as favorable, with no toxic or adverse effects observed; the main complaint was mild swallowing discomfort from large capsules.
